- Burning Rock Biotech press release (NASDAQ:BNR): Q4 GAAP EPS of -$0.22.
- Revenue of $17.1M (-14.9% Y/Y).
- Cash, cash equivalents, restricted cash were $86.7 million as of December 31, 2023.
2024 Financial Guidance: The company said that it expects to achieve breakeven (measured by non-GAAP gross profit minus non-GAAP SG&A) in the first half of 2024.
Burning Rock Biotech GAAP EPS of -$0.22, revenue of $17.1M
Recommended For You
More Trending News
About BNR Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| BNR | - | - |
| Burning Rock Biotech Limited | ||